Financial Bone Therapeutics to broaden and derisk therapeutic portfolio by acquiring majority participation in Medsenic byChris StewartAugust 10, 2022
Biologics Bone Therapeutics to strategically focus on lead cell therapy product ALLOB byChris StewartMarch 29, 2022
Biologics Extremities Financial Spine Top Stories Bone Therapeutics and Link Health sign a non-binding term sheet for the global rights of ALLOB byChris StewartNovember 29, 2021
Biologics Top Stories Bone Therapeutics provides update on the progress of clinical studies byChris StewartJuly 19, 2021
Biologics Extremities Bone Therapeutics treats first patient in ALLOB Phase IIb tibial fracture study byChris StewartJanuary 13, 2021
Biologics Spine Bone Therapeutics’ allogeneic cell therapy product, ALLOB, shows 90% fusion rate at 24 months in Phase IIa study in lumbar spinal fusion byChris StewartOctober 14, 2020
Biologics Extremities Financial Bone Therapeutics, Link Health and Pregene to develop and commercialize the ALLOB allogeneic bone cell therapy platform in China and Southeast Asia byJosh SandbergOctober 5, 2020
Biologics Recon Bone Therapeutics treats first patients in pivotal JTA-004 phase III knee osteoarthritis study byChris StewartMay 18, 2020
Biologics Financial Bone Therapeutics Provides First Quarter 2020 Business Update byJosh SandbergMay 6, 2020
Biologics Extremities Bone Therapeutics appoints Stefanos Theoharis as Chief Business Officer byJosh SandbergMarch 26, 2020
